SaxenaPRFerrariMDFrom serotonin receptor classification to the antimigraine drug sumatriptan.Cephalalgia1992;
12:
187–96
2.
PilgrimALessons learned from the clinical development of sumatriptan. In:
OlesenJTfelt-HansenP, editors.
Headache treatment. Trial methodology and new drugs.
Philadelphia:
Lippincott-Raven,
1997:
119–24
3.
OsborneMJAustinRCDawsonKJLangeLIs there a problem with long-term use of sumatriptan in migraine?Br Med J1994;
308:
113
4.
KaubeHMayADienerHCPfaffenrathVSumatriptan.Br Med J1994;
308:
1573–4
5.
JensenKGaistDOveruse of sumatriptan [in Danish].Ugeskr Laeger1994;
156:
7554
GundersonCHThe impact of new pharmaceutical agents on the cost of neurologic care.Neurology1995;
45:
569–72
8.
WilkinsonMPfaffenrathVSchoenenJDienerHCSteinerTJMigraine and cluster headache—their management with sumatriptan; a critical review of the current clinical experience.Cephalalgia1995;
15:
337–57
9.
Headache Classification Committee of the International Headache Society.Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain.
Cephalalgia1988;
8Suppl 7:
1–96
10.
StewartWFLiptonRBCelentanoDDReedMLPrevalence of migraine headache in the United States.JAMA1992;
267:
64–9
11.
HenryPMichelPBrochetBDartiguesJFTisonSSalamonRA nationwide survey of migraine in France: prevalence and clinical features in adults.Cephalalgia1992;
12:
229–37
12.
RasmussenBKJensenRSchrollMOlesenJEpidemiology of headache in a general population—a prevalence study.J Clin Epidemiol1991;
44:
1147–57
13.
O'BrienBGoereeRStreinerDPrevalence of migraine headache in Canada: a population-based survey.Int J Epidemiol1994;
23:
1020–6
14.
RussellMBRasmussenBKThorvaldsenPOlesenJPrevalence and sex-ratio of the subtypes of migraine.Int J Epidemiol1995;
24:
612–8
15.
RasmussenBKJensenROlesenJImpact of headache on sickness absence and utilisation of medical services: a Danish population study.J Epidemiol Community Health1992;
46:
443–6
16.
WelchKMDrug therapy of migraine.N Engl J Med1993;
329:
1476–83
17.
NappiGRussellDTension-type headache, cluster headache, and miscellaneous headaches. Clinical features. In:
OlesenJ, editor.
The headaches.
New York:
Raven Press,
1993:
577–84
18.
KrabbeACluster headache: a review.Acta Neurol Scand1986;
74:
1–9
19.
ManzoniGCTerzanoMGBonoGMicieliGMartucciNNappiGCluster headache—clinical findings in 180 patients.Cephalalgia1983;
3:
21–30
20.
EkbomKAhlborgBSchéleRPrevalence of migraine and cluster headache in Swedish men of 18.Headache1978;
18:
9–19
21.
D'AlessandroRGamberiniGBenassiGMorgantiGCortelliPLugaresiECluster headache in the Republic of San Marino.Cephalalgia1986;
6:
159–62
22.
RasmussenBKJensenRSchrollMOlesenJInterrelations between migraine and tension-type headache in the general population.Arch Neurol1992;
49:
914–8
23.
RasmussenBKEpidemiology of tension-type headache. In:
OlesenJTfelt-HansenPWelchKMA, editors.
The headaches.
New York:
Raven Press,
1993:
439–43
24.
LiptonRBSchwartzBSStewartWFEpidemiology of tension-type headache [Abstract].Cephalalgia1997;
17:
233
25.
BatemanDNSumatriptan.Lancet1993;
341:
221–4
26.
DechantKLClissoldSPSumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache.Drugs1992;
43:
776–98
HumphreyPPAGoadsbyPJThe mode of action of sumatriptan is vascular? A debate.Cephalalgia1994;
14:
401–10
29.
The Subcutaneous Sumatriptan International Study Group.Treatment of migraine attacks with sumatriptan.N Engl J Med1991;
325:
316–21
30.
CadyRKWendtJKKirchnerJRSargentJDRothrockJFSkaggsHJTreatment of acute migraine with subcutaneous sumatriptan.JAMA1991;
265:
2831–5
31.
VisserWHFerrariMDBaylissEMLudlowSPilgrimATreatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study.Cephalalgia1992;
12:
308–13
32.
The Oral Sumatriptan Dose-Defining Study Group.Sumatriptan—an oral dose-defining study.Eur Neurol1991;
31:
300–5
33.
The Sumatriptan Auto-Injector Study Group.Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device.Eur Neurol1991;
31:
323–31
34.
The Oral Sumatriptan International Multiple-Dose Study Group.Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine.Eur Neurol1991;
31:
306–13
35.
GoadsbyPJZagamiASDonnanGAOral sumatriptan in acute migraine.Lancet1991;
338:
782–3
36.
Tfelt-HansenPSumatriptan for the treatment of migraine—a review of controlled clinical trials.Cephalalgia1993;
13:
238–44
37.
NappiGSicuteriFByrneMRoncolatoMZerbiniOOral sumatriptan compared with placebo in the acute treatment of migraine.J Neurol1994;
241:
138–44
38.
The Sumatriptan Cluster Headache Study Group.Treatment of acute cluster headache with sumatriptan.N Engl J Med1991;
325:
322–6
39.
RussellMBHolm-ThomsenOERish⊘j NielsenMClealAPilgrimAJOlesenJA randomized, double-blind, placebo-controlled, crossover study of subcutaneous sumatriptan in general practice.Cephalalgia1994;
14:
291–6
40.
JensenKTfelt-HansenPHansenEWKr⊘isEHPedersenOSIntroduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice.Cephalalgia1995;
15:
423–9
41.
FerrariMDSaxenaPRClinical and experimental effects of sumatriptan in humans.Tips1993;
14:
129–33
42.
The Multinational Oral Sumatriptan and Cafergot Comparative Study Group.A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine.Eur Neurol1991;
31:
314–22
43.
Tfelt-HansenPHenryPMulderLScheldewaertRGSchoenenJChazotGThe effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine.Lancet1995;
346:
923–6
44.
WinnerPRicaldeOLe ForceBSaperJMargulBA double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.Arch Neurol1996;
53:
180–4
45.
VisserWHJaspersNMWHde VriendRHMFerrariMDRisk factors for headache recurrence after sumatriptan: a study in 366 migraine patients.Cephalalgia1996;
16:
264–9
46.
FerrariMDJamesMHBatesDOral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences.Cephalalgia1994;
14:
330–8
47.
VisserWHBurggraafJMullerLMPharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response.Clin Pharmacol Ther1996;
60:
452–60
48.
The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group.A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine.Eur Neurol1992;
32:
177–84
49.
BatesDAshfordEDawsonRSubcutaneous sumatriptan during the migraine aura.Neurology1994;
44:
1587–92
50.
TanseyMJPilgrimAJMartinPMLong-term experience with sumatriptan in the treatment of migraine.
Eur Neurol199333:
310–5
51.
GrossMLPTurnerAMJewsburyJClealALLong-term efficacy of subcutaneous sumatriptan using a novel self-injector.Headache1995;
35:
601–6
52.
BrownEGEndersbyCASmithRNTalbotJCThe safety and tolerability of sumatriptan: an overview.
Eur Neurol199131:
339–44
53.
SullivanJTPrestonKLTestaMPBuschMJasinskiDRPsychoactivity and abuse potential of sumatriptan.Clin Pharmacol Ther1992;
52:
635–42
54.
WillettFCurzenNAdamsJArmitageMCoronary vasospasm induced by subcutaneous sumatriptan.
Br Med J1992304:
1415
55.
AbrahamsenBChristiansenBDAngina pectoris after sumatriptan (Imigran) [in Danish].Ugeskr Laeger1992;
154:
3602–3
56.
StriekerBHCoronary vasospasm and sumatriptan [Letter; comment].Br Med J1992;
305:
118
57.
OttervangerJPvan WitsenTBValkenburgHAStrickerBHPostmarketing study of cardiovascular adverse reactions associated with sumatriptan.Br Med J1993;
307:
1185
58.
KellyKMCardiac arrest following use of sumatriptan.Neurology1995;
45:
1211–3
59.
OttervangerJPvan WitsenTBValkenburgHAGrobbeeDEStricherBHCAdverse reactions attributed to sumatriptan. A postmarketing study in general practice.Eur J Clin Pharmacol1994;
47:
305–9
60.
VisserWHJapsersNMWHde VriendRHMFerrariMDChest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients.Cephalalgia1996;
15:
554–9
61.
ChesterAHMartinGRBodelssonM5-Hydroxy-tryptamine receptor profile in healthy and diseased human epicardial coronary arteries.Cardiovasc Res1990;
24:
932–7
62.
KaumannAJFrenkenMPosivalHBrownAMVariable participation of 5-HT1-like receptors and 5-HT1D-betareceptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT1D-betareceptors.Circulation1994;
90:
1141–53
63.
MacIntyrePDBhargavaBHoggKJGemmillJDHillisWSThe effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation.Br J Clin Pharmacol1992;
34:
541–6
64.
MacIntyrePDBhargavaBHoggKJGemmillJDHillisWSEffect of subcutaneous sumatriptan, a selective 5-HT1-agonist, on the systemic, pulmonary, and coronary circulation.Circulation1993;
87:
401–5
65.
OttervangerJPStrickerBHChCardiovascular reactions to sumatriptan. Cause for concern?CNS Drugs1995;
3:
90–8
66.
PloskerGLMcTavishDSumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache.Drugs1994;
47:
622–51
67.
BrennumJKjeldsenMOlesenJThe 5-HT1-like agonist sumatriptan has a significant effect in chronic tension-type headache.Cephalalgia1992;
12:
375–9
68.
BrennumJKjeldsenMBrinckTSumatriptan in the treatment of tension-type headache:219–22. In:
OlesenJTfelt-HansenP, editors.
Headache treatment. Trial methodology and new drugs.
Philadelphia:
Lippincott-Raven,
1997
69.
BrennumJBrinckTSchriverLSumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache.Eur J Neurol1996;
3:
23–8
SaperJRJonesMErgotamine tartrate dependency: features and possible mechanisms.Clin Neuropharmacol1986;
9:
244–56
72.
MathewNTKurmanRPerezFDrug induced refractory headache—clinical features and managementHeadache1990;
30:
634–8
73.
PilgrimAJMethodology of clinical trials of sumatriptan in migraine and cluster headache.Eur Neurol1991;
31:
295–9
74.
PiniLATrentiTDoes chronic use of sumatriptan induce dependence?Headache1994;
34:
600
75.
LacrerenzaMMarchettiniPSmirneSMigraine transformed into chronic daily headache by sumatriptan overuse [Abstract].Ital J Neurol Sci1993;
7Suppl 14:
130
76.
CatarciTLenziGLCerboRFieschiCSumatriptan and daily headache.J Neurol Neurosurg Psych1995;
58:
508–18
77.
CelentanoDDStewartWFLiptonRBReedMLMedication use and disability among migraineurs: a national probability sample survey.Headache1992;
32:
223–8
78.
EdmeadsJFindlayHTugwellPPryse PhillipsWNelsonRFMurrayTJImpact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey.Can J Neurol Sci1993;
20:
131–7
79.
RasmussenBKEpidemiology of headache [Thesis].Copenhagen:
Copenhagen University,
1994
80.
BlauJNDrummondMFMigraine.London:
Office of Health Economics,
1991
81.
SteinerTLong-term cost-benefit assessment of antimigraine drugs.
Cephalalgia1995;
Suppl 15:
37–40
82.
OsterhausJTGuttermanDLPlatchetkaJRHealthcare resource and lost labour costs of migraine headache in the US.Pharmacoeconomics1992;
2:
67–76
83.
CullREWellsNEJMiocevichMLThe economic cost of migraine.Br J Med Econ1992;
2:
103–15
84.
de LissovoyGLazarusSSThe economic cost of migraine. Present state of knowledge.Neurology1994;
44:
S56–62
85.
S⊘rensenHTLarsenBOA population-based Danish data resource with possible high validity in pharmacoepidemiological research.J Med Syst1994;
18:
33–8
86.
GaistDS⊘rensenHTHallasJThe Danish Prescription Registries.Dan Med Bull1997;
44:
445–8
87.
Statistical information [in Danish].
Copenhagen: Danish Department of Statistics,
1996
88.
Statistical yearbook [in Danish].
Copenhagen: Danish Department of Statistics,
1995
Consumption of cholesterol-lowering drugs [in Danish].
Copenhagen: Medicines Division, National Board of Health,
1995
91.
Medicines Division.
Treatment of manifest osteoporosis with calcium, vitamin D and bisfosfonates [in Danish]. Copenhagen: Medicines Division, National Board of Health,
1996
92.
WHO Collaborating Centre for Drug Statistics Methodology.Anatomical Therapeutic Chemical (ATC) classification index including Defined Daily Doses (DDDs) for plain substances.
Oslo:
WHO,
1995
93.
MorrisJAGardnerMJCalculating confidence intervals for relative risks, odds ratios, and standardised ratios and rates. In:
GardnerMJAltaianDG, editors.
Statistics with confidence.
London:
Br Med J,
1989:
50–63
94.
HallasJNissenAIndividualized drug utilization statistics. Analysing a population's drug use from the perspective of individual users.Eur J Clin Pharmacol1994;
47:
367–72
95.
RussellMBRasmussenBKBrennumJIversenHKJensenRAOlesenJPresentation of a new instrument: the diagnostic headache diary.Cephalalgia1992;
12:
369–74
96.
S⊘rensenHTHansenIEjlersenESabroeSHamburgerHIdentification of patients treated with strong analgesics: an assessment of two Danish information systems with respect to epidemiological research.J Med Syst1996;
20:
57–65
97.
NielsenGLSerensenHTPedersenABSabroeSAnalysis of data quality in registries concerning diabetes mellitus—a comparison between a population based hospital discharge and an insulin prescription registry.J Med Syst1996;
20:
1–10
98.
S⊘rensenHTSteffensenFHEjlersenEM⊘ller-PetersenJKristensenKResearch in the Danish Health Service System: completeness and validity of prescription data illustrated by utilization of oral anticoagulants.Int J Risk Safety Med1995;
7:
33–41
99.
GoldbergJGelfandHLevyPSRegistry evaluation methods: a review and case study.Epidemiol Rev1980;
2:
210–20
100.
S⊘rensenHTSabroeSOlsenJA framework for evaluation of secondary data sources for epidemiological research.Int J Epidemiol1996;
25:
435–42
101.
BeardonPHMcGilchristMMMcKendrickADMcDevittDGMacDonaldTMPrimary non-compliance with prescribed medication in primary care.Br Med J1993;
307:
846–8
102.
Validity and reliability studies. In:
ArmstrongBKWhiteESaracciR, editors.
Principles of exposure measurement in epidemiology. Oxford: Oxford University Press,
1992:
78–114
103.
HarlowSDLinetMSAgreement between questionnaire data and medical records. The evidence for accuracy of recall.Am J Epidemiol1989;
129:
233–48
104.
NorellSEAccuracy of patient interviews and estimates by clinical staff in determining medication compliance.Soc Sci Med1981;
15:
57–61
105.
LauHSde BoerAKlerkxMPorsiusACompleteness of medication histories in hospital medical records [Abstract].Pharmacoepidemiol Drug Safety1996;
5:
s60
106.
MitchellAACottierLBShapiroSEffect of questionnaire design on recall of drug exposure in pregnancy.Am J Epidemiol1986;
123:
670–6
107.
WestSLSavitzDAKochGStromBLGuessHAHartzemaARecall accuracy for prescription medications: self report compared with database information.Am J Epidemiol1995;
142:
1103–12
108.
HallasJGaistDBjerrumLThe waiting-time distribution: a graphical approach to epidemiological measures of drug utilization.
Epidemiology1997.
In press
109.
Hester VisserWde VriendRHMJaspersNMHWFerrariMDSumatriptan in clinical practice: a 2-year review of 453 migraine patients.Neurology1996;
47:
46–51
110.
EkbomKWaldenlindEColeJPilgrimAKirkhamASumatriptan in chronic cluster headache: results of continuous treatment for eleven months.Cephalalgia1992;
12:
254–6
RosholmJ-UHallasJGramLFConcurrent use of more than one major psychotropic drug (polypsychopharmacy) in outpatients—a prescription database study.Br J Clin Pharmacol1994;
37:
533–8
123.
GaistDSindrupSHallasJGramLFMisuse of sumatriptan.Lancet1994;
344:
1090
124.
GaistDHallasJHansenN-ChGGramLFAre young adults with asthma treated sufficiently with inhaled steroids? A population-based study of prescription data from 1991 and 1994.Br J Clin Pharmacol1996;
41:
285–9
125.
HallasJEvidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis.Epidemiology1996;
7:
478–84
126.
RosholmJ-UGramLFIsacsonGHallasJChanges in the pattern of antidepressant use upon the introduction of the new antidepressants: a prescription database study.Eur J Clin Pharmacol1997;
52:
205–9
127.
HallasJLauritsenJMVilladsenHDGramLFNonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high risk groups by excess risk estimates.Scand J Gastroenterol1995;
30:
438–44
128.
OlsenJHS⊘rensenHTFriisSCancer risk in users of calcium channel blockers.Hypertension1997;
29:
1091–4
129.
Tfelt-HansenPKrabbeAErgotamine abuse. Do patients benefit from withdrawal?Cephalalgia1981;
1:
29–32
130.
SchniderPAullSBaumgartnerCLong-term outcome of patients with headache and drug abuse after inpatient withdrawal: five-year follow-up.Cephalalgia1996;
16:
481–5
131.
SilbersteinSDYoungWBAnalgesic rebound headache. How great is the problem and what can be done?Drug Safety1995;
13:
133–44
132.
ReljaGNiderGGrandiFCKoscicaNNegroCMuscoGCefalea cronica da abuso di sumatriptan: descrizione di 9 casi [in Italian with English summary].Confinia cephalalgica1996;
5:
11–5
